ME02016B - Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola - Google Patents
Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triolaInfo
- Publication number
- ME02016B ME02016B MEP-2015-9A MEP915A ME02016B ME 02016 B ME02016 B ME 02016B ME P915 A MEP915 A ME P915A ME 02016 B ME02016 B ME 02016B
- Authority
- ME
- Montenegro
- Prior art keywords
- dioxabicyclo
- chloro
- hydroxymethyl
- phenyl
- compound
- Prior art date
Links
- WAFOSDMKSJGJBX-UHFFFAOYSA-N octane-2,3,4-triol Chemical class CCCCC(O)C(O)C(C)O WAFOSDMKSJGJBX-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 15
- -1 (1R,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxybenzyl)phenyl]-2,3,4-trihydroxy-6,8-dioxabicyclo[3.2.1]oct-1 -ylmethyl ester Chemical class 0.000 claims 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- AXJQVVLKUYCICH-OAQYLSRUSA-N (4s)-5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-n'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C=1C=C(Cl)C=CC=1C([C@H](C1)C=2C=CC=CC=2)=NN1C(=NC)NS(=O)(=O)C1=CC=C(Cl)C=C1 AXJQVVLKUYCICH-OAQYLSRUSA-N 0.000 claims 2
- GVIYUKXRXPXMQM-BPXGDYAESA-N 221231-10-3 Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CSSC1)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C(C)C)=O)C1=CC=C(O)C=C1 GVIYUKXRXPXMQM-BPXGDYAESA-N 0.000 claims 2
- 108010011459 Exenatide Proteins 0.000 claims 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims 2
- 108010019598 Liraglutide Proteins 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 2
- 239000000883 anti-obesity agent Substances 0.000 claims 2
- 229940125708 antidiabetic agent Drugs 0.000 claims 2
- 239000003472 antidiabetic agent Substances 0.000 claims 2
- 229940125710 antiobesity agent Drugs 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229960001519 exenatide Drugs 0.000 claims 2
- 229960002701 liraglutide Drugs 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 2
- XLJINMDXOSTAIJ-BHPIROGQSA-N (1s,2s,3s,4r,5s)-5-[4-chloro-3-[(4-ethoxyphenyl)-hydroxymethyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol Chemical compound C1=CC(OCC)=CC=C1C(O)C1=CC([C@@]23O[C@@](CO)(CO2)[C@@H](O)[C@H](O)[C@H]3O)=CC=C1Cl XLJINMDXOSTAIJ-BHPIROGQSA-N 0.000 claims 1
- DRGJFMXQRZCMIH-CUUWFGFTSA-N (1s,2s,3s,4r,5s)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(fluoromethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@@]23O[C@@](CF)(CO2)[C@@H](O)[C@H](O)[C@H]3O)=CC=C1Cl DRGJFMXQRZCMIH-CUUWFGFTSA-N 0.000 claims 1
- UHORDSFKUFJGMW-KNJMJIDISA-N (1s,2s,3s,4r,5s)-5-[4-chloro-3-[(4-hydroxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol Chemical compound C=1C([C@]23OC[C@](O2)([C@H]([C@H](O)[C@H]3O)O)CO)=CC=C(Cl)C=1CC1=CC=C(O)C=C1 UHORDSFKUFJGMW-KNJMJIDISA-N 0.000 claims 1
- XLJINMDXOSTAIJ-HQZKGGBDSA-N (1s,2s,3s,4r,5s)-5-[4-chloro-3-[(r)-(4-ethoxyphenyl)-hydroxymethyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol Chemical compound C1=CC(OCC)=CC=C1[C@@H](O)C1=CC([C@@]23O[C@@](CO)(CO2)[C@@H](O)[C@H](O)[C@H]3O)=CC=C1Cl XLJINMDXOSTAIJ-HQZKGGBDSA-N 0.000 claims 1
- XLJINMDXOSTAIJ-BPIQYHPVSA-N (1s,2s,3s,4r,5s)-5-[4-chloro-3-[(s)-(4-ethoxyphenyl)-hydroxymethyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol Chemical compound C1=CC(OCC)=CC=C1[C@H](O)C1=CC([C@@]23O[C@@](CO)(CO2)[C@@H](O)[C@H](O)[C@H]3O)=CC=C1Cl XLJINMDXOSTAIJ-BPIQYHPVSA-N 0.000 claims 1
- RXWPVTPWNBLJFF-CUUWFGFTSA-N (1s,2s,3s,4r,5s)-5-[4-chloro-3-[[4-(2-hydroxyethoxy)phenyl]methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol Chemical compound C1=CC(OCCO)=CC=C1CC1=CC([C@@]23O[C@@](CO)(CO2)[C@@H](O)[C@H](O)[C@H]3O)=CC=C1Cl RXWPVTPWNBLJFF-CUUWFGFTSA-N 0.000 claims 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims 1
- AMNXBQPRODZJQR-DITALETJSA-N (2s)-2-cyclopentyl-2-[3-[(2,4-dimethylpyrido[2,3-b]indol-9-yl)methyl]phenyl]-n-[(1r)-2-hydroxy-1-phenylethyl]acetamide Chemical compound C1([C@@H](C=2C=CC=C(C=2)CN2C3=CC=CC=C3C3=C(C)C=C(N=C32)C)C(=O)N[C@@H](CO)C=2C=CC=CC=2)CCCC1 AMNXBQPRODZJQR-DITALETJSA-N 0.000 claims 1
- QJLPWVUZFKETMK-LLVKDONJSA-N (5r)-1,5,7,9,11,14-hexahydroxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carboxylic acid Chemical compound O=C1C2=C(O)C=C(O)C=C2C(=O)C2=C1C(O)=C1C[C@@H](O)C(C=C(C(=C3O)C(O)=O)C)=C3C1=C2O QJLPWVUZFKETMK-LLVKDONJSA-N 0.000 claims 1
- HQSRVYUCBOCBLY-XOOFNSLWSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2s,4r)-2-(4-chlorophenyl)-2-[(4-methyl-1,2,4-triazol-3-yl)sulfanylmethyl]-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CSC=4N(C=NN=4)C)(OC3)C=3C=CC(Cl)=CC=3)=CC=2)C=C1 HQSRVYUCBOCBLY-XOOFNSLWSA-N 0.000 claims 1
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 claims 1
- HMXDWDSNPRNUKI-UHFFFAOYSA-N 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-3-pyrazolecarboxamide Chemical compound CCC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Br)C=C1 HMXDWDSNPRNUKI-UHFFFAOYSA-N 0.000 claims 1
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 claims 1
- IETKPTYAGKZLKY-UHFFFAOYSA-N 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N=1C2=CC=CC=C2C(=O)N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O IETKPTYAGKZLKY-UHFFFAOYSA-N 0.000 claims 1
- 108010070305 AOD 9604 Proteins 0.000 claims 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 claims 1
- QJLPWVUZFKETMK-UHFFFAOYSA-N Pradimicin Q Natural products O=C1C2=C(O)C=C(O)C=C2C(=O)C2=C1C(O)=C1CC(O)C(C=C(C(=C3O)C(O)=O)C)=C3C1=C2O QJLPWVUZFKETMK-UHFFFAOYSA-N 0.000 claims 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims 1
- OCTNNXHKAOLDJL-BMGYQPLYSA-N Salbostatin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)OC[C@@H]1N[C@@H]1[C@H](O)[C@@H](O)[C@H](O)C(CO)=C1 OCTNNXHKAOLDJL-BMGYQPLYSA-N 0.000 claims 1
- OCTNNXHKAOLDJL-UHFFFAOYSA-N Salbostatin Natural products OC1C(O)C(CO)OCC1NC1C(O)C(O)C(O)C(CO)=C1 OCTNNXHKAOLDJL-UHFFFAOYSA-N 0.000 claims 1
- QLYKJCMUNUWAGO-GAJHUEQPSA-N Taranabant Chemical compound N([C@@H](C)[C@@H](CC=1C=CC(Cl)=CC=1)C=1C=C(C=CC=1)C#N)C(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 QLYKJCMUNUWAGO-GAJHUEQPSA-N 0.000 claims 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 claims 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 1
- 229930186167 Trestatin Natural products 0.000 claims 1
- IMIPDPVHGGHVNH-YWVHRCQQSA-N [(8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] (z)-octadec-9-enoate Chemical compound C1C[C@]2(C)C(=O)CC[C@H]2[C@@H]2CCC3=CC(OC(=O)CCCCCCC\C=C/CCCCCCCC)=CC=C3[C@H]21 IMIPDPVHGGHVNH-YWVHRCQQSA-N 0.000 claims 1
- 229960002632 acarbose Drugs 0.000 claims 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims 1
- 229960001466 acetohexamide Drugs 0.000 claims 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 claims 1
- 229960001667 alogliptin Drugs 0.000 claims 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 claims 1
- 229950010663 balaglitazone Drugs 0.000 claims 1
- 108010042362 beta-Lipotropin Proteins 0.000 claims 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
- 229960002802 bromocriptine Drugs 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 claims 1
- 229950002397 cetilistat Drugs 0.000 claims 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 claims 1
- 229950009226 ciglitazone Drugs 0.000 claims 1
- QQKNSPHAFATFNQ-UHFFFAOYSA-N darglitazone Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 claims 1
- 229950006689 darglitazone Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- TUOSYWCFRFNJBS-BHVANESWSA-N dirlotapide Chemical compound O=C([C@@H](NC(=O)C=1N(C2=CC=C(NC(=O)C=3C(=CC=CC=3)C=3C=CC(=CC=3)C(F)(F)F)C=C2C=1)C)C=1C=CC=CC=1)N(C)CC1=CC=CC=C1 TUOSYWCFRFNJBS-BHVANESWSA-N 0.000 claims 1
- 229960002551 dirlotapide Drugs 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- IQQBRKLVEALROM-UHFFFAOYSA-N drinabant Chemical compound C=1C(F)=CC(F)=CC=1N(S(=O)(=O)C)C(C1)CN1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 IQQBRKLVEALROM-UHFFFAOYSA-N 0.000 claims 1
- 229950002375 englitazone Drugs 0.000 claims 1
- 150000002168 ethanoic acid esters Chemical class 0.000 claims 1
- 235000019439 ethyl acetate Nutrition 0.000 claims 1
- 108010015174 exendin 3 Proteins 0.000 claims 1
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 claims 1
- 229960001381 glipizide Drugs 0.000 claims 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims 1
- 229950005809 implitapide Drugs 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 229960005060 lorcaserin Drugs 0.000 claims 1
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 229960001110 miglitol Drugs 0.000 claims 1
- 229950000884 mitratapide Drugs 0.000 claims 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 1
- 229960003086 naltrexone Drugs 0.000 claims 1
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 claims 1
- 229950003861 obinepitide Drugs 0.000 claims 1
- LDUARVOCMXITCM-ILMFCTMOSA-N obinepitide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 LDUARVOCMXITCM-ILMFCTMOSA-N 0.000 claims 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims 1
- 229960001243 orlistat Drugs 0.000 claims 1
- UNAZAADNBYXMIV-UHFFFAOYSA-N otenabant Chemical compound C1CC(NCC)(C(N)=O)CCN1C1=NC=NC2=C1N=C(C=1C(=CC=CC=1)Cl)N2C1=CC=C(Cl)C=C1 UNAZAADNBYXMIV-UHFFFAOYSA-N 0.000 claims 1
- 229950005009 otenabant Drugs 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- AZUIUVJESCFSLJ-UHFFFAOYSA-N phenyl 6-[[3-methoxy-2-[4-(trifluoromethyl)phenyl]benzoyl]amino]-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C=1C=C(C(F)(F)F)C=CC=1C=1C(OC)=CC=CC=1C(=O)NC(C=C1CC2)=CC=C1CN2C(=O)OC1=CC=CC=C1 AZUIUVJESCFSLJ-UHFFFAOYSA-N 0.000 claims 1
- 229960005095 pioglitazone Drugs 0.000 claims 1
- 229960003611 pramlintide Drugs 0.000 claims 1
- 108010029667 pramlintide Proteins 0.000 claims 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 claims 1
- 229940016667 resveratrol Drugs 0.000 claims 1
- 235000021283 resveratrol Nutrition 0.000 claims 1
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 claims 1
- 229960003015 rimonabant Drugs 0.000 claims 1
- 229960004586 rosiglitazone Drugs 0.000 claims 1
- 229960004937 saxagliptin Drugs 0.000 claims 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims 1
- 108010033693 saxagliptin Proteins 0.000 claims 1
- 229960004425 sibutramine Drugs 0.000 claims 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims 1
- 229960004034 sitagliptin Drugs 0.000 claims 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims 1
- 229950003174 surinabant Drugs 0.000 claims 1
- 229950005022 taranabant Drugs 0.000 claims 1
- 229950001790 tendamistat Drugs 0.000 claims 1
- 108010037401 tendamistate Proteins 0.000 claims 1
- 229960005371 tolbutamide Drugs 0.000 claims 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims 1
- 229960001641 troglitazone Drugs 0.000 claims 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 229960001254 vildagliptin Drugs 0.000 claims 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (15)
1. Spoj Formule (A) ili Formule (B)naznačen time štoR je -OH ili, kada je R1 -O-C(O)-(C1-C4)alkil ili -O-C(O)-aril, R je isti kao R1 ili -OH;R1 je -OH, F, Cl, -O-C(O)-(C1-C4)alkil, -O-C(O)-aril, -O-C(O)-O-(C1-C4)alkil ili -O-C(O)-O-aril; iR2 je -OH, -O-(C1-C4)alkil ili -O-CH2-CH2-O-R2a; uz uvjet da kada je R -OH, a R1 je -OH, R2 je -OH ili -O-CH2-CH2-O-R2a;R2a je H, -C(O)-(C1-C4)alkil, -C(O)-aril, -C(O)-O-(C1-C4)alkil ili -C(O)-O-aril;i njihove farmaceutski prihvatljive soli.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je navedeni spoj spoj Formule (A).
3. Spoj u skladu s patentnim zahtjevima 1 ili 2, naznačen time što je R1 -OH.
4. Spoj u skladu s patentnim zahtjevom 3, naznačen time što je R2 -OH.
5. Spoj u skladu s patentnim zahtjevom 3, naznačen time što je R2 -O-CH2CH2OH.
6. Spoj, naznačen time što ga se bira iz skupine koju čine: (1R,2S,3S,4R,5S)-3,4-diacetoksi-1-acetoksimetil-5-[4-klor-3-(4-etoksibenzil)fenil]-6,8-dioksabiciklo[3.2.1]okt-2-ilni ester octene kiseline; (1R,2S,3S,4R,5S)-5-[4-klor-3-(4-etoksibenzil)fenil]-2,3,4-trihidroksi-6,8-dioksabiciklo[3.2.1]okt-1-ilmetilni ester octene kiseline; (1R,2S,3S,4R,5S)-5-[4-klor-3-(4-etoksibenzil)fenil]-2,3,4-trihidroksi-6,8-dioksabiciklo[3.2.1]okt-1-ilmetilni ester etilni ester ugljične kiseline; (1S,2S,3S,4R,5S)-5-[4-klor-3-(4-[D5]etoksibenzil)fenil]-1-hidroksimetil-6,8-dioksabiciklo[3.2.1]oktan-2,3,4-triol; 2-{4-[2-klor-5-((1S,2S,3S,4R,5S)-2,3,4-trihidroksi-1-hidroksimetil-6,8-dioksabiciklo[3.2.1]okt-5-il)benzil]fenoksi}etilni ester octene kiseline; (1S,2S,3S,4R,5S)-5-{4-klor-3-[4-(2-hidroksietoksi)benzil]fenil}-1-hidroksimetil-6,8-dioksabiciklo[3.2.1]oktan-2,3,4-triol; i (1S,2S,3S,4R,5S)-5-[4-klor-3-(4-etoksibenzil)fenil]-1-fluormetil-6,8-dioksabiciklo[3.2.1]oktan-2,3,4-triol; ili njihove farmaceutski prihvatljive soli.
7. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je navedeni spoj (1S,2S,3S,4R,5S)-5-[4-klor-3-(4-hidroksibenzil)fenil]-1-hidroksimetil-6,8-dioksabiciklo[3.2.1]oktan-2,3,4-triol.
8. Spoj, naznačen time što ga se bira iz skupine koju čine: (1S,2S,3S,4R,5S)-5-{4-klor-3-[(4-etoksifenil)hidroksimetil]fenil}-1-hidroksimetil-6,8-dioksabiciklo[3.2.1]oktan-2,3,4-triol; (1S,2S,3S,4R,5S)-5-{4-klor-3-[(R)-(4-etoksifenil)hidroksimetil]fenil}-1-hidroksimetil-6,8-dioksabiciklo[3.2.1]oktan-2,3,4-triol; i (1S,2S,3S,4R,5S)-5-{4-klor-3-[(S)-(4-etoksifenil)hidroksimetil]fenil}-1-hidroksimetil-6,8-dioksabiciklo[3.2.1]oktan-2,3,4-triol.
9. Farmaceutski pripravak, naznačen time što sadrži: (i) spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, ili njegovu farmaceutski prihvatljivu sol; i (ii) farmaceutski prihvatljivu pomoćni tvar, razrjeđivač, ili podlogu.
10. Pripravak u skladu s patentnim zahtjevom 9, naznačen time što je navedeni spoj, ili navedena njegova terapijski prihvatljiva sol, prisutan u terapijski djelotvornoj količini.
11. Pripravak u skladu s patentnim zahtjevima 9 ili 10, naznačen time što dodatno sadrži najmanje jedno dodatno farmaceutsko sredstvo, koje se bira iz skupine koju čine sredstvo protiv pretilosti i antidijabetično sredstvo.
12. Pripravak u skladu s patentnim zahtjevom 11, naznačen time što navedeno sredstvo protiv pretilosti se bira iz skupine koju čine rimonabant, taranabant, surinabant, otenabant, SLV319 (CAS No. 464213-10-3), AVE1625 (CAS No. 358970-97-5)), dirlotapid, mitratapid, implitapid, R56918 (CAS No. 403987), CAS No. 913541-47-6, lorkaserin, cetilistat, PYY3-36, naltrekson, oleoil-estron, obinepitid, pramlintid, tesofenzin, leptin, liraglutid, bromokriptin, orlistat, eksenatid, AOD-9604 (CAS No. 221231-10-3) i sibutramin.
13. Pripravak u skladu s patentnim zahtjevom 11, naznačen time što navedeni antidijabetično sredstvo se bira iz skupine koju čine metformin, acetoheksamid, klorpropamid, Diabinese, glibenklamid, glipizid, gliburid, glimepirid, gliklazid, glipentid, glikidon, glizolamid, tolazamid, tolbutamid, tendamistat, trestatin, akarboza, adipozin, kamigliboza, emiglitat, miglitol, vogliboza, pradimicin-Q, salbostatin, balaglitazon, ciglitazon, darglitazon, englitazon, isaglitazon, pioglitazon, rosiglitazon, troglitazon, eksendin-3, eksendin-4, liraglutid, troduskvemin, rezveratrol, hirtiosalni ekstrakt, sitagliptin, vildagliptin, alogliptin i saksagliptin.
14. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, ili njegova farmaceutski prihvatljiva sol, ili pripravak u skladu s bilo kojim od patentnih zahtjeva 9 do 13, naznačen time što je namijenjen upotrebi u liječenju pretilosti i poremećaja povezanih s pretilošću kod životinja.
15. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, ili njegova farmaceutski prihvatljiva sol, ili pripravak u skladu s bilo kojim od patentnih zahtjeva 9 do 13, naznačen time što je namijenjen upotrebi u liječenju ili odgađanju napredovanja ili početka dijabetesa tip 2 i poremećaja povezanih s dijabetesom kod životinja. Pfizer Inc. Zastupani po:
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25714009P | 2009-11-02 | 2009-11-02 | |
| US37293810P | 2010-08-12 | 2010-08-12 | |
| PCT/IB2010/054775 WO2011051864A1 (en) | 2009-11-02 | 2010-10-21 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| EP10776433.4A EP2496583B1 (en) | 2009-11-02 | 2010-10-21 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02016B true ME02016B (me) | 2015-05-20 |
Family
ID=43297093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-9A ME02016B (me) | 2009-11-02 | 2010-10-21 | Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US8669380B2 (me) |
| EP (1) | EP2496583B1 (me) |
| JP (1) | JP5696156B2 (me) |
| KR (1) | KR101426180B1 (me) |
| AP (1) | AP3099A (me) |
| AU (1) | AU2010310956B2 (me) |
| CA (1) | CA2777857C (me) |
| CR (1) | CR20120289A (me) |
| DK (1) | DK2496583T3 (me) |
| EA (1) | EA021983B1 (me) |
| EC (1) | ECSP12011946A (me) |
| ES (1) | ES2527179T3 (me) |
| GE (1) | GEP20146104B (me) |
| HR (1) | HRP20150107T1 (me) |
| ME (1) | ME02016B (me) |
| NZ (1) | NZ599945A (me) |
| PL (1) | PL2496583T3 (me) |
| PT (1) | PT2496583E (me) |
| RS (1) | RS53827B1 (me) |
| SI (1) | SI2496583T1 (me) |
| WO (1) | WO2011051864A1 (me) |
| ZA (1) | ZA201203486B (me) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102372722A (zh) * | 2010-08-10 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用 |
| US9480755B2 (en) * | 2011-06-03 | 2016-11-01 | Ratiopharm Gmbh | Pharmaceutical composition comprising dapagliflozin and cyclodextrin |
| AR086922A1 (es) * | 2011-06-13 | 2014-01-29 | Panacea Biotec Ltd | Derivados de 3,4,5-trihidroxi-6-(hidroximetil)tetrahidro-2h-pirano utiles para el tratamiento de diabetes y dislipidemias, composiciones farmaceuticas que los contienen y metodo para prepararlos |
| EP2755722B1 (en) | 2011-09-13 | 2017-05-24 | Panacea Biotec Ltd. | Novel sglt inhibitors |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| EP2934568B1 (en) | 2012-12-21 | 2017-10-18 | Sanofi | Dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| ES2740299T3 (es) * | 2013-03-14 | 2020-02-05 | Msd Int Gmbh | Métodos para preparar inhibidores de SGLT2 |
| CN104619713B (zh) * | 2013-05-24 | 2017-06-16 | 四川海思科制药有限公司 | 氧杂双环衍生物、制备方法及其应用 |
| WO2015027963A1 (zh) * | 2013-09-02 | 2015-03-05 | 四川海思科制药有限公司 | 芳环类衍生物、其药物组合物及其应用 |
| US9394329B2 (en) | 2013-09-27 | 2016-07-19 | Sunshine Lake Pharma Co., Ltd. | Glucopyranosyl derivatives and their uses in medicine |
| PT3145934T (pt) | 2014-05-19 | 2020-12-31 | Pfizer | Compostos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol substituídos como agentes de direcionamento de asgpr |
| CN105461762B (zh) * | 2014-09-27 | 2018-12-04 | 广东东阳光药业有限公司 | 吡喃葡萄糖基衍生物及其在医药上的应用 |
| MX377172B (es) | 2015-03-03 | 2025-03-07 | Saniona As | Formulacion de combinacion de tesofensina y betabloqueante |
| CN105646604A (zh) * | 2016-03-01 | 2016-06-08 | 孙霖 | 埃格列净晶型b及制备方法 |
| CN105646603A (zh) * | 2016-03-01 | 2016-06-08 | 孙霖 | 埃格列净晶型a及制备方法 |
| CN107382952B (zh) * | 2017-07-13 | 2020-02-28 | 杭州科巢生物科技有限公司 | 埃格列净的制备方法及其中间体 |
| CN107857768A (zh) * | 2018-01-04 | 2018-03-30 | 威海贯标信息科技有限公司 | 一种埃格列净新晶型 |
| WO2020026273A1 (en) * | 2018-07-31 | 2020-02-06 | Msn Laboratories Private Limited, R&D Center | Solid forms of ertugliflozin free base and solid dispersions comprising ertugliflozin l-pyroglutamic acid. |
| CN111269241A (zh) * | 2018-12-05 | 2020-06-12 | 广西久福生物科技有限公司 | 一种新型化合物及其制备方法与应用 |
| WO2021137144A1 (en) * | 2019-12-31 | 2021-07-08 | Hikal Limited | An efficient process for the preparation of ertugliflozin l-pyroglutamic acid and intermediates thereof |
| CN113214263B (zh) * | 2020-02-06 | 2022-09-30 | 北京桦冠医药科技有限公司 | 瑞德西韦关键中间体的一种合成方法 |
| CN117624265A (zh) * | 2023-11-27 | 2024-03-01 | 江苏海悦康医药科技有限公司 | 艾托格列净杂质的合成方法 |
Family Cites Families (175)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3174901A (en) | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| JPS5373598A (en) * | 1976-12-11 | 1978-06-30 | Teikoku Chem Ind Corp Ltd | Saccharide derivatives and process for thir preparation |
| IE52768B1 (en) | 1981-04-06 | 1988-02-17 | Boots Co Ltd | 1-arylcyclobutylalkylamine compounds useful as therapeutic agents |
| JPS5911600B2 (ja) * | 1981-04-30 | 1984-03-16 | 理化学研究所 | ３−アジド−１，６−アンヒドロ−３−デオキシ−２，４−ジ−Ｏ−ベンジル−β−Ｄ−グルコピラノ−ス及びその製造法 |
| CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| US4590201A (en) | 1984-02-02 | 1986-05-20 | Merck & Co., Inc. | 5-amino or substituted amino 1,2,3-triazoles |
| GB8531071D0 (en) | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
| NZ214774A (en) | 1986-01-08 | 1989-10-27 | Nz Scientific & Ind Res | Herbicidal and/or plant growth regulatory compositions based on 1,6-anhydro-beta-hexopyranose derivatives and certain of these derivatives |
| US5043142A (en) | 1986-10-30 | 1991-08-27 | Terumo Kabushiki Kaisha | Alpha-hydroperoxyisopropylphenyl compounds and process for preparing the same |
| US5041541A (en) | 1988-05-05 | 1991-08-20 | The Procter & Gamble Company | Functional sugar substituted with reduced calories |
| WO1991009537A1 (en) | 1989-12-21 | 1991-07-11 | The Procter & Gamble Company | Food compositions containing reduced calorie fats and reduced calorie sugars |
| CN1020944C (zh) | 1990-01-30 | 1993-05-26 | 阿图尔-费希尔股份公司费希尔厂 | 紧固件 |
| WO1993007167A1 (en) | 1991-10-04 | 1993-04-15 | The Procter & Gamble Company | Cholesterol lowering compounds and process for making them |
| CA2079544A1 (en) | 1991-10-04 | 1993-04-05 | Adam Weislaw Mazur | Cholesterol lowering compounds |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| TW406086B (en) | 1996-12-26 | 2000-09-21 | Tanabe Seiyaku Co | Propiophenone derivatives and process for preparing the same |
| WO1998041648A2 (en) | 1997-03-20 | 1998-09-24 | Variagenics, Inc. | Target genes for allele-specific drugs |
| US6486299B1 (en) | 1998-09-28 | 2002-11-26 | Curagen Corporation | Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity |
| US6069238A (en) | 1998-09-30 | 2000-05-30 | Eli Lilly And Company | Spirocyclic C-glycosides |
| IL148384A0 (en) | 1999-08-31 | 2002-09-12 | Kissei Pharmaceutical | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US20020034799A1 (en) | 1999-12-10 | 2002-03-21 | Gregory Donoho | Novel human transporter protein and polynucleotides encoding the same |
| US6627611B2 (en) | 2000-02-02 | 2003-09-30 | Kotobuki Pharmaceutical Co Ltd | C-glycosides and preparation of thereof as antidiabetic agents |
| WO2001057214A2 (en) | 2000-02-03 | 2001-08-09 | Lexicon Genetics Incorporated | Human transporter proteins and polynucleotides encoding the same |
| DE10006887A1 (de) | 2000-02-16 | 2001-09-06 | Hermann Koepsell | Verbindungen, die die Aktivität oder die Konzentration des Regulatorproteins RS1 verändern |
| DE60115623T2 (de) | 2000-03-17 | 2006-07-06 | Kissei Pharmaceutical Co., Ltd., Matsumoto | Glucopyranosyloxy-benzylbenzen-derivate, medizinische zusammensetzung und zwischenprodukte für die herstellung der derivate |
| US6555519B2 (en) | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
| US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| KR100647204B1 (ko) | 2000-09-29 | 2006-11-17 | 깃세이 야쿠힌 고교 가부시키가이샤 | 글루코피라노실옥시벤질벤젠 유도체 및 그것을 함유하는의약조성물 |
| EP1338603B1 (en) | 2000-11-02 | 2010-01-20 | Ajinomoto Co., Inc. | Novel pyrazole derivatives and diabetes remedies containing the same |
| US7053060B2 (en) | 2000-11-30 | 2006-05-30 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| US20020081678A1 (en) | 2000-12-11 | 2002-06-27 | Gennady Merkulov | Isolated nucleic acid molecules encoding human transporter proteins, and uses thereof |
| WO2002053738A1 (fr) | 2000-12-28 | 2002-07-11 | Takeda Chemical Industries, Ltd. | Nouvelles proteines et adn correspondant |
| IL156678A0 (en) | 2000-12-28 | 2004-01-04 | Kissei Pharmaceutical | Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
| TWI255817B (en) | 2001-02-14 | 2006-06-01 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
| CA2438593C (en) | 2001-02-26 | 2010-09-21 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and medicinal use thereof |
| CA2438595C (en) | 2001-02-27 | 2011-08-09 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and medicinal use thereof |
| PL210793B1 (pl) | 2001-02-28 | 2012-03-30 | Merck & Co Inc | Acylowane pochodne piperydyny |
| US6936590B2 (en) | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| EP1419251A4 (en) | 2001-03-27 | 2005-05-04 | Applera Corp | HUMAN ISOLATED TRANSPORTER PROTEINS, NUCLEIC ACID MOLECULES ENCODING THESE HUMAN CARRIER PROTEINS AND USES THEREOF |
| US20030045553A1 (en) | 2001-04-04 | 2003-03-06 | Bussolari Jacqueline C. | Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators |
| US6838442B2 (en) | 2001-04-04 | 2005-01-04 | Ortho-Mcneil Pharmaceutical, Inc. | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators |
| AU2002338643A1 (en) | 2001-04-10 | 2002-10-28 | Millennium Pharmaceuticals, Inc. | 68723, sodium/glucose cotransporter family members and uses therefor |
| CA2444481A1 (en) | 2001-04-11 | 2002-10-24 | Bristol-Myers Squibb Company | Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
| CA2672001A1 (en) | 2001-04-27 | 2002-11-07 | Ajinomoto Co., Inc. | N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same |
| EP1400529A4 (en) | 2001-05-30 | 2007-12-19 | Kissei Pharmaceutical | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF |
| WO2003000712A1 (en) | 2001-06-20 | 2003-01-03 | Kissei Pharmaceutical Co., Ltd. | Nitrogenous heterocyclic derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor |
| JP4115105B2 (ja) | 2001-07-02 | 2008-07-09 | 協和醗酵工業株式会社 | ピラゾール誘導体 |
| JPWO2003011880A1 (ja) | 2001-07-31 | 2004-11-18 | キッセイ薬品工業株式会社 | グルコピラノシルオキシベンジルベンゼン誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
| EP1432720A1 (en) | 2001-09-05 | 2004-06-30 | Bristol-Myers Squibb Company | O-pyrazole glucoside sglt2 inhibitors and method of use |
| WO2003056329A2 (en) | 2001-12-21 | 2003-07-10 | 7Tm Pharma A/S | Use of a signal transduction complex in drug discovery processes |
| AU2002358469A1 (en) | 2001-12-21 | 2003-07-15 | 7Tm Pharma A/S | Modified receptors for the discovery of therapeutic ligands |
| WO2003056005A1 (fr) | 2001-12-27 | 2003-07-10 | Takeda Chemical Industries, Ltd. | Promoteur homologue de sglt humain et utilisation dudit promoteur |
| DE10212557A1 (de) | 2002-03-14 | 2003-09-25 | Univ Schiller Jena | Verfahren zur Charakterisierung hochparallelisierter Liquidhandlingtechnik mittels Mikroplatten sowie Testkit zur Durchführung des Verfahrens |
| US7371730B2 (en) | 2002-03-22 | 2008-05-13 | Kissei Pharmaceutical Co., Ltd. | Crystals of glucopyranosyloxybenzyl benzene derivative |
| US20070059356A1 (en) | 2002-05-31 | 2007-03-15 | Almarsson Oern | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| DE10225844A1 (de) | 2002-06-04 | 2003-12-18 | Lang Florian | sgk und nedd als diagnostische und therapeutische targets |
| DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| TWI254635B (en) | 2002-08-05 | 2006-05-11 | Yamanouchi Pharma Co Ltd | Azulene derivative and salt thereof |
| KR100985502B1 (ko) | 2002-08-08 | 2010-10-05 | 깃세이 야쿠힌 고교 가부시키가이샤 | 피라졸 유도체,그것을 함유하는 의약 조성물, 그 의약용도 및 그 제조 중간체 |
| TW200409778A (en) | 2002-08-09 | 2004-06-16 | Taisho Pharmaceutical Co Ltd | Process for selective production of aryl 5-thio- β-D-aldohexopyranosides |
| JP2004137245A (ja) | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
| JP4606876B2 (ja) | 2002-08-27 | 2011-01-05 | キッセイ薬品工業株式会社 | ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途 |
| US20060063711A1 (en) | 2002-10-29 | 2006-03-23 | Keiji Iwamoto | Use of sglt homolog |
| JP4651934B2 (ja) | 2002-12-04 | 2011-03-16 | キッセイ薬品工業株式会社 | ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途 |
| US20060035844A1 (en) | 2002-12-04 | 2006-02-16 | Fumiaki Ito | Preventive or remedy for diseases caused by hyperglycemia |
| DE10258007B4 (de) | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| DE10258008B4 (de) | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| JP4679155B2 (ja) | 2002-12-25 | 2011-04-27 | キッセイ薬品工業株式会社 | 含窒素複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
| WO2004063209A2 (en) | 2003-01-03 | 2004-07-29 | Bristol-Myers Squibb Company | Methods of producing c-aryl glucoside sglt2 inhibitors |
| EP1601795A4 (en) | 2003-03-07 | 2008-03-26 | Threshold Pharmaceuticals Inc | METHOD FOR DETERMINING THE SENSITIVITY OF A TUMOR AGAINST TREATMENT WITH AN ANTI-TUMBER AGENT |
| ES2363941T3 (es) | 2003-03-14 | 2011-08-19 | Astellas Pharma Inc. | Derivados de c-glucósido para el tratamiento de diabetes. |
| JP2004300102A (ja) | 2003-03-31 | 2004-10-28 | Kissei Pharmaceut Co Ltd | 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
| US7439232B2 (en) | 2003-04-01 | 2008-10-21 | Taisho Pharmaceutical Co., Ltd. | Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same |
| JPWO2004089967A1 (ja) | 2003-04-01 | 2006-07-06 | 大正製薬株式会社 | ヘテロアリール５−チオ−β−Ｄ−グルコピラノシド誘導体及びそれを含有する糖尿病治療薬 |
| WO2004093544A1 (ja) | 2003-04-24 | 2004-11-04 | Ishihara Sangyo Kaisha, Ltd. | 置換ベンゼン誘導体又はその塩、それらの製造方法、並びにそれらを有効成分として含有する殺菌剤 |
| AU2003902263A0 (en) | 2003-05-12 | 2003-05-29 | Fujisawa Pharmaceutical Co., Ltd. | Monosaccharide compounds |
| JPWO2004106352A1 (ja) | 2003-05-29 | 2006-07-20 | 大正製薬株式会社 | アルドヘキソピラノース中間体の製造法 |
| JP2004359630A (ja) | 2003-06-06 | 2004-12-24 | Yamanouchi Pharmaceut Co Ltd | ジフルオロジフェニルメタン誘導体及びその塩 |
| JP4708187B2 (ja) | 2003-06-20 | 2011-06-22 | キッセイ薬品工業株式会社 | ピラゾール誘導体、それを含有する医薬組成物及びその製造中間体 |
| ES2402098T5 (es) | 2003-08-01 | 2021-06-09 | Mitsubishi Tanabe Pharma Corp | Compuestos novedosos que tienen actividad inhibidora frente a transportador dependiente de sodio |
| EP1680414A4 (en) | 2003-08-01 | 2009-05-27 | Janssen Pharmaceutica Nv | SUBSTITUTED INDAZOLE-O-GLUCOSIDE |
| UA86042C2 (en) | 2003-08-01 | 2009-03-25 | Янссен Фармацевтика Н.В. | Substituted indazole-o-glucosides |
| WO2005012318A2 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica Nv | Substituted fused heterocyclic c-glycosides |
| TW200526678A (en) | 2003-08-01 | 2005-08-16 | Janssen Pharmaceutica Nv | Substituted indole-O-glucosides |
| WO2005012242A2 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica Nv | Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides |
| US7375090B2 (en) | 2003-08-26 | 2008-05-20 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof |
| EP1660509B1 (de) | 2003-08-26 | 2009-02-04 | Boehringer Ingelheim International GmbH | Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| US7371732B2 (en) | 2003-12-22 | 2008-05-13 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture |
| JP2005247834A (ja) | 2004-02-04 | 2005-09-15 | Taisho Pharmaceut Co Ltd | ナトリウム依存性グルコース供輸送体２の活性阻害剤 |
| NZ549219A (en) | 2004-03-04 | 2010-08-27 | Kissei Pharmaceutical | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
| EP1724278B1 (en) | 2004-03-04 | 2014-05-07 | Kissei Pharmaceutical Co., Ltd. | Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs |
| AU2005219779B2 (en) | 2004-03-04 | 2011-04-14 | Kissei Pharmaceutical Co., Ltd. | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
| CA2557801C (en) | 2004-03-16 | 2013-06-25 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof |
| US20070185197A1 (en) | 2004-03-31 | 2007-08-09 | Hideki Fujikura | Phenol derivative, medicinal composition containing the same, and medicinal use thereof |
| WO2005095373A1 (ja) | 2004-03-31 | 2005-10-13 | Kissei Pharmaceutical Co., Ltd. | ナフタレン誘導体、それを含有する医薬組成物およびその医薬用途 |
| WO2005095372A1 (ja) | 2004-03-31 | 2005-10-13 | Kissei Pharmaceutical Co., Ltd. | ナフタレン誘導体、それを含有する医薬組成物及びその医薬用途 |
| WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
| BRPI0510273A (pt) | 2004-05-25 | 2007-10-30 | Pfizer Prod Inc | derivados de tetraazabenzo[e]azuleno e análogos destes |
| DE102004028241B4 (de) | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
| US7393836B2 (en) | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
| US20070293690A1 (en) | 2004-07-08 | 2007-12-20 | Hiroshi Tomiyama | Process for Production of Azulene Derivatives and Intermediates for the Synthesis of the Same |
| GB0415365D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| DE102004034690A1 (de) | 2004-07-17 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| ES2581331T3 (es) | 2004-07-21 | 2016-09-05 | Kissei Pharmaceutical Co., Ltd. | Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática |
| TW200606129A (en) | 2004-07-26 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same |
| JP2008508213A (ja) | 2004-07-27 | 2008-03-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｄ−グルコピラノシル−フェニル置換環状体、そのような化合物を含有する医薬品、それらの使用及びその製造方法 |
| WO2006018150A1 (de) | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| AR051446A1 (es) | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
| JP2006117651A (ja) | 2004-09-27 | 2006-05-11 | Taisho Pharmaceut Co Ltd | Ｓｇｌｔ２の活性阻害剤 |
| US20080139484A1 (en) | 2004-09-29 | 2008-06-12 | Kissei Pharmaceutical Co., Ltd. | 1(Beta-D-Glycopyranosyl)-3-Substituted Nitrogenous Heterocyclic Compound, Medicinal Composition Containing the Same, and Medicinal Use Thereof |
| DE102004048388A1 (de) | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| JP5086643B2 (ja) | 2004-11-18 | 2012-11-28 | キッセイ薬品工業株式会社 | １−置換−３−（β−Ｄ−グリコピラノシル）含窒素ヘテロ環化合物、及びそれを含有する医薬 |
| JP2008007405A (ja) | 2004-12-07 | 2008-01-17 | Takeda Chem Ind Ltd | カルボキサミド誘導体 |
| CA2587639A1 (en) | 2004-12-16 | 2006-06-22 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| TW200637839A (en) | 2005-01-07 | 2006-11-01 | Taisho Pharmaceutical Co Ltd | 1-thio-d-glucitol derivatives |
| TW200637869A (en) | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| CA2597269A1 (en) | 2005-02-15 | 2006-08-24 | Kissei Pharmaceutical Co., Ltd. | 1-substituted-7-(beta-d-glycopyranosyloxy)(aza)indole compound and pharmaceutical containing the same |
| DE602006009772D1 (de) | 2005-02-23 | 2009-11-26 | Boehringer Ingelheim Int | Glucopyranosylsubstituierte ((hetero)arylethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters typ 2 (sglt2) |
| WO2006090577A1 (ja) | 2005-02-24 | 2006-08-31 | Mayekawa Mfg. Co., Ltd. | ロース・ばら部の肋骨脱骨方法及び装置 |
| EP1710246A1 (en) | 2005-04-08 | 2006-10-11 | Schering Aktiengesellschaft | Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer |
| ES2338041T3 (es) | 2005-04-15 | 2010-05-03 | Boehringer Ingelheim International Gmbh | Derivados de (heteroariloxi-bencil)-benceno sustituidos con glucopiranosilo en calidad de inhibidores de sglt. |
| WO2006108584A2 (en) | 2005-04-15 | 2006-10-19 | Cenix Bioscience Gmbh | Human marker genes and agents for cardiovascular disorders and artherosclerosis |
| WO2006115137A1 (ja) | 2005-04-22 | 2006-11-02 | Kissei Pharmaceutical Co., Ltd. | ２－アミノベンズイミダゾール誘導体及びその医薬用途 |
| US20070009615A1 (en) | 2005-04-29 | 2007-01-11 | Litao Zhong | Compositions and methods for controlling glucose uptake |
| US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| JP4297972B2 (ja) | 2005-05-27 | 2009-07-15 | アクテリオン ファーマシューティカルズ リミテッド | 新規なピペリジンカルボン酸アミド誘導体 |
| WO2007000445A1 (en) | 2005-06-29 | 2007-01-04 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| TW200726755A (en) | 2005-07-07 | 2007-07-16 | Astellas Pharma Inc | A crystalline choline salt of an azulene derivative |
| CA2616294A1 (en) | 2005-07-27 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors |
| UY29694A1 (es) | 2005-07-28 | 2007-02-28 | Boehringer Ingelheim Int | Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido |
| WO2007019526A2 (en) | 2005-08-05 | 2007-02-15 | Naturegen, Inc. | Compositions and methods for controlling glucose and lipid uptake from foods |
| EP1924571B1 (en) | 2005-08-30 | 2010-10-13 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| RU2008113050A (ru) | 2005-09-08 | 2009-10-20 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-(4-ЭТИНИЛБЕНЗИН)-БЕНЗОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ |
| WO2007029668A1 (ja) | 2005-09-08 | 2007-03-15 | National University Corporation Kanazawa University | ソフトイオン化法のための誘導体化試薬 |
| AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
| US20070099237A1 (en) | 2005-10-31 | 2007-05-03 | The Regents Of The University Of Michigan | Reaction co-crystallization of molecular complexes or co-crystals |
| KR20080102395A (ko) | 2006-02-15 | 2008-11-25 | 베링거 인겔하임 인터내셔날 게엠베하 | 글루코피라노실-치환된 벤조니트릴 유도체, 당해 화합물을 함유하는 약제학적 조성물, 이들의 용도 및 이들의 제조방법 |
| TWI370818B (en) | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
| EP1854806A1 (en) | 2006-05-02 | 2007-11-14 | MPG Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Thioglycosides as pharmaceutically active agents |
| JP2009167104A (ja) | 2006-05-02 | 2009-07-30 | Taisho Pharmaceutical Co Ltd | フェニル５−チオグリコシド化合物 |
| JP2009167103A (ja) | 2006-05-02 | 2009-07-30 | Taisho Pharmaceutical Co Ltd | ピラゾリル５−チオグリコシド化合物 |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| RU2437876C2 (ru) | 2006-05-19 | 2011-12-27 | Тайсо Фармасьютикал Ко., Лтд. | Соединение с-фенилглицитола для лечения диабета |
| EP2019679B1 (en) * | 2006-05-23 | 2018-06-20 | Theracos, Inc. | Glucose transport inhibitors and methods of use |
| DE102006028862A1 (de) | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3-Amino-imidazo[1,2-a]pyridinderivate |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| KR20090023570A (ko) | 2006-06-29 | 2009-03-05 | 다이쇼 세이야꾸 가부시끼가이샤 | Ｃ-페닐 1-티오글루시톨 화합물 |
| JP2008050353A (ja) | 2006-07-27 | 2008-03-06 | Mitsubishi Tanabe Pharma Corp | 医薬組成物 |
| TWI403516B (zh) | 2006-07-27 | 2013-08-01 | Chugai Pharmaceutical Co Ltd | To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes |
| TWI418556B (zh) | 2006-07-27 | 2013-12-11 | Mitsubishi Tanabe Pharma Corp | 吲哚衍生物 |
| TWI432446B (zh) | 2006-07-27 | 2014-04-01 | Chugai Pharmaceutical Co Ltd | 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用 |
| US20080027014A1 (en) | 2006-07-28 | 2008-01-31 | Tanabe Seiyaku Co., Ltd. | Novel SGLT inhibitors |
| TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
| US8039441B2 (en) | 2006-08-15 | 2011-10-18 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture |
| WO2008034859A1 (en) | 2006-09-21 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| TWI499414B (zh) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法 |
| US20100093744A1 (en) | 2006-10-13 | 2010-04-15 | Chugai Seiyaku Kabushiki Kaisha | Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes |
| DE102006048728A1 (de) | 2006-10-16 | 2008-04-17 | Merck Patent Gmbh | 3-Amino-imidazo{1,2-a]pyridinderivate |
| JP2010507629A (ja) | 2006-10-27 | 2010-03-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ４−（β−Ｄ−グルコピラノス−１−イル）−１−メチル−２−［４−（（Ｓ）−テトラヒドロフラン−３−イルオキシ）−ベンジル］−ベンゼンの結晶形、その製造方法及び医薬品を製造するための使用 |
| CA2668623A1 (en) | 2006-11-06 | 2008-05-15 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
| NZ598778A (en) | 2006-11-09 | 2013-09-27 | Boehringer Ingelheim Int | Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions |
| UY30801A1 (es) | 2006-12-18 | 2008-07-03 | Smithkline Beecham Corp | Compuestos calciliticos |
| US7846945B2 (en) | 2007-03-08 | 2010-12-07 | Lexicon Pharmaceuticals, Inc. | Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use |
| WO2008115574A1 (en) | 2007-03-21 | 2008-09-25 | Reliant Pharmaceuticals, Inc. | Cb1 antagonist and a dyslipidemic agent and/or metabolic regulator, and methods of making and using same |
| TW200904454A (en) | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof |
| EA017411B1 (ru) | 2007-07-26 | 2012-12-28 | Лексикон Фармасьютикалз, Инк. | Способы и соединения, предназначенные для получения ингибиторов котранспортера натрий-глюкозы 2 типа |
| CL2008002425A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta. |
| UA99924C2 (en) | 2007-08-23 | 2012-10-25 | Теракос, Инк. | Benzylbenzol derivatives and using thereof |
| CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| PL2334687T3 (pl) * | 2008-08-28 | 2012-05-31 | Pfizer | Pochodne dioksabicyklo[3.2.1]oktano-2,3,4-triolu |
-
2010
- 2010-10-21 NZ NZ599945A patent/NZ599945A/en unknown
- 2010-10-21 ES ES10776433.4T patent/ES2527179T3/es active Active
- 2010-10-21 AP AP2012006281A patent/AP3099A/xx active
- 2010-10-21 KR KR1020127014234A patent/KR101426180B1/ko active Active
- 2010-10-21 GE GEAP201012727A patent/GEP20146104B/en unknown
- 2010-10-21 ME MEP-2015-9A patent/ME02016B/me unknown
- 2010-10-21 HR HRP20150107AT patent/HRP20150107T1/hr unknown
- 2010-10-21 US US13/498,702 patent/US8669380B2/en active Active
- 2010-10-21 EA EA201290267A patent/EA021983B1/ru unknown
- 2010-10-21 DK DK10776433.4T patent/DK2496583T3/en active
- 2010-10-21 WO PCT/IB2010/054775 patent/WO2011051864A1/en not_active Ceased
- 2010-10-21 PL PL10776433T patent/PL2496583T3/pl unknown
- 2010-10-21 JP JP2012535982A patent/JP5696156B2/ja active Active
- 2010-10-21 AU AU2010310956A patent/AU2010310956B2/en active Active
- 2010-10-21 SI SI201030838T patent/SI2496583T1/sl unknown
- 2010-10-21 PT PT107764334T patent/PT2496583E/pt unknown
- 2010-10-21 RS RS20150085A patent/RS53827B1/sr unknown
- 2010-10-21 CA CA2777857A patent/CA2777857C/en active Active
- 2010-10-21 EP EP10776433.4A patent/EP2496583B1/en active Active
-
2012
- 2012-05-14 ZA ZA2012/03486A patent/ZA201203486B/en unknown
- 2012-05-30 CR CR20120289A patent/CR20120289A/es unknown
- 2012-06-04 EC ECSP12011946 patent/ECSP12011946A/es unknown
-
2013
- 2013-03-12 US US13/796,339 patent/US20130225487A1/en not_active Abandoned
-
2014
- 2014-11-07 US US14/535,556 patent/US9439901B2/en active Active
- 2014-11-07 US US14/535,613 patent/US9439902B2/en active Active
- 2014-11-07 US US14/535,630 patent/US9308204B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02016B (me) | Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola | |
| JP2013509393A5 (me) | ||
| US6500838B2 (en) | Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors | |
| JP2011521940A5 (me) | ||
| CN116710446B (zh) | Glp-1r激动剂的晶型及其用途 | |
| US8846765B2 (en) | Pharmaceutical combination | |
| JP2017519025A5 (me) | ||
| RU2006133898A (ru) | Производные бензимидазола и его применение | |
| NZ542690A (en) | Muscarinic M1 receptor agonists for pain management | |
| EA004657B1 (ru) | Фармацевтическая композиция на основе обладающих антихолинергическим действием соединений , способ ее получения и применение | |
| RU2006133118A (ru) | Средство для чрескожного введения никотина | |
| KR20040044953A (ko) | 요실금 치료를 위한, 무스카린 길항제와 선택된오피오이드와의 배합물 | |
| CA2685126C (en) | Therapeutic or prophylactic agent for dyskinesia | |
| EP3265466A1 (en) | Peripheral-anticholinergic muscarinic agonist combination | |
| AU2003277077B2 (en) | Use of nefopam for the treatment of nausea or emesis | |
| JP2007500676A (ja) | 抗コリン作用薬とベータ受容体刺激薬を含む吸入用薬剤 | |
| AU700520B2 (en) | NK-1 receptor antagonists for the treatment of cancer | |
| WO2018111795A2 (en) | Use of sgc stimulators for the treatment of esophageal motility disorders | |
| AU2002327635B2 (en) | Enhancement of learning and memory and treatment of amnesia | |
| WO2007061868A2 (en) | Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors | |
| AU2002327635A1 (en) | Enhancement of learning and memory and treatment of amnesia | |
| RU2022100958A (ru) | Комбинированная терапия агонистами gpr119 и ингибиторами dpp-4 | |
| US20060167114A1 (en) | Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors | |
| AU2022366192A1 (en) | Trpc6 inhibitory compounds for treating sepsis | |
| WO2024148149A2 (en) | Compositions and methods for controlling glucose levels |